2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.52 Incidence, Patterns, and Clinical Outcomes of Brain Metastases in Young Adults with KRAS-altered Non-Small Cell Lung Cancer

PP01.52 Incidence, Patterns, and Clinical Outcomes of Brain Metastases in Young Adults with KRAS-altered Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study explores the incidence, patterns, and clinical outcomes of brain metastases in young patients with non-small cell lung cancer (NSCLC) characterized by KRAS alterations. The research primarily focuses on two cohorts: patients with KRAS G12C mutations and those with non-G12C KRAS mutations.<br /><br />Key findings indicate that about 50% of young patients with NSCLC have KRAS G12C alterations, while the remaining harbor non-G12C mutations. The study notes that young NSCLC patients, ages 18-50, often present with brain metastases, a pattern more common at diagnosis compared to older demographics. Approximately 30% of young patients with KRAS-altered NSCLC develop brain metastases.<br /><br />The research highlights important distinctions in brain metastasis development between the cohorts. Patients with non-G12C mutations generally have a longer median time to the development of central nervous system (CNS) metastases (12 months vs. 5 months for the G12C cohort). However, NSCLC patients with non-G12C mutations also tend to have slightly shorter CNS-specific overall survival (OS) compared to those with G12C alterations.<br /><br />From a demographic perspective, the cohort is predominantly Caucasian and has a significant proportion of current smokers. The overall survival rates between patients with G12C and non-G12C mutations were not significantly different, with median OS reported at approximately 19.3 months for the G12C cohort and 22.5 months for the non-G12C group, though these differences were not statistically significant (p=0.6785).<br /><br />The study suggests that young patients with G12C mutations may experience slightly better CNS-specific outcomes than those with non-G12C mutations, highlighting potential implications for personalized treatment strategies. Overall, this research underscores the need for targeted interventions and further study on the management of KRAS-altered NSCLC in young patients.

Asset Subtitle

Jinesh Gheeya

Keywords

brain metastases

young patients

non-small cell lung cancer

NSCLC

KRAS alterations

G12C mutations

non-G12C mutations

central nervous system metastases

overall survival

personalized treatment